---
title: "礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元"
description: "礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274805260.md"
published_at: "2026-02-04T11:47:20.000Z"
---

# 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元

> 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。

礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。

风险提示及免责条款

市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

### Related Stocks

- [LLY.US - 礼来](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [XLV.US - 医疗业 ETF - SPDR](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [VHT.US - 医疗业 ETF - Vanguard](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [SBIO.US - 医药突破 ETF - ALPS](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [XBI.US - 标普生物技术 ETF - SPDR](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [IHE.US - 美国制药 ETF - iShares](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [PBE.US - 动态生物技术与基因组 ETF - Invesco](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [IBB.US - 纳斯达克生物科技指数 ETF - iShares Nasdaq](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [FBT.US - 纽交所高增长板生物技术指数 ETF - First Trust](https://longbridge.com/zh-CN/quote/FBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Lilly to launch multi-dose weight-loss drug device in US | Eli Lilly has received FDA approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, which will be avail | [Link](https://longbridge.com/zh-CN/news/276609508.md) |
| Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership | Goldman Sachs analyst Asad Haider has reaffirmed a Buy rating on Eli Lilly & Co. with a price target of $1,260.00, citin | [Link](https://longbridge.com/zh-CN/news/276723737.md) |
| ANALYSIS-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs | Novo Nordisk's latest trial data for its obesity drug CagriSema shows it underperformed compared to Eli Lilly's Zepbound | [Link](https://longbridge.com/zh-CN/news/276684872.md) |
| Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push | Eli Lilly has launched the Zepbound KwikPen, a multi-dose injector that holds a month's worth of tirzepatide, designed t | [Link](https://longbridge.com/zh-CN/news/276615033.md) |
| Lilly adds multidose Zepbound pens to self-pay menu | Eli Lilly has introduced multidose Zepbound KwikPens to its self-pay menu, following FDA approval. Each pen contains fou | [Link](https://longbridge.com/zh-CN/news/276610573.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。